Last mentioned: Feb 21, 2026
Closing of Private Placement
Expected completion of the $1.0 million common share offering and debenture issuance.
Financing Upsized
Rakovina announces an increase in its funding round to $2.0 million due to investor demand.
Operational Milestone
Anticipated use of funds for lead candidate advancement or IND-enabling studies.
Rakovina Therapeutics has announced an upsized financing package totaling up to $2.0 million, split between convertible debentures and a private placement. The capital injection is earmarked for near-term operations as the company advances its DNA-damage response (DDR) oncology programs.
Rakovina Therapeutics has announced an upsized financing package totaling $2.0 million through a combination of convertible debentures and a private placement. The capital infusion is earmarked for near-term operations as the company advances its DNA damage response (DDR) cancer therapies.